NCT02286557 is a Phase 2 clinical trial of Methelphenidate in Fatigue in Multiple Sclerosis, sponsored by Kessler Foundation.

Who is sponsoring NCT02286557?

NCT02286557 is sponsored by Kessler Foundation.

What drugs are being tested in NCT02286557?

Interventions in NCT02286557: Methelphenidate, Placebo.

What condition does NCT02286557 study?

NCT02286557 studies Fatigue in Multiple Sclerosis.

Is NCT02286557 still recruiting?

NCT02286557 is currently completed. Last updated 25 August 2025.

Last reviewed 2025-08-25 · How we verify

NCT02286557

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial

Completed Phase 2 Last updated 25 August 2025

What this trial tests

Phase 2 trial testing Methelphenidate in Fatigue in Multiple Sclerosis in 36 participants. Completed in 4 March 2025.

Timeline

1 October 2014

Primary endpoint
28 February 2025

4 March 2025

Quick facts

Lead sponsor	Kessler Foundation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	36
Start date	1 October 2014
Primary completion	28 February 2025
Estimated completion	4 March 2025
Sites	1 location across United States

Drugs / interventions tested

Methelphenidate — full drug profile →
Placebo

Conditions studied

Fatigue in Multiple Sclerosis — all drugs for Fatigue in Multiple Sclerosis →

Sponsor

Kessler Foundation

Who can join

Adults 18 to 65, any sex, with Fatigue in Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fatigue - Modified Fatigue Impact Scale
Time frame: baseline, day 30 and day 68
Changes on fatigue levels from baseline, will be assess after 4 weeks, and after 10 weeks of the duration of the study.

Sponsor's own description

Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities. The goal of this project is to test whether methylphenidate (MP), a well-known psychostimulant, can effective treat fatigue experienced by individuals with MS. The current study will test the effect of MP on MS fatigue through a clinical trial. Every participant in the study will be exposed to both the drug and the placebo for a period of time. Both the investigators and participants will be unaware whether participants are receiving the drug or the placebo. Upon successful completion of the study, physicians will be able to evaluate the potential prescription of MP to treat fatigue in persons with MS based on solid research evidence. Importantly, MP is already an FDA approved widely used medication in multiple clinical populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kessler Foundation trials

Trials by the same sponsor.

NCT07168941 — Evaluation and Refinement of KF-STRIDE Into the Interview! · NA · not yet recruiting
NCT07159100 — tDCS for Cancer-Related Fatigue and Weakness · EARLY_PHASE1 · not yet recruiting
NCT06886152 — Spinal Stimulation and Gait Training to Improve Mobility in TBI · NA · not yet recruiting
NCT07073313 — Using Muscle Functional MRI to Study Spatial Muscle Activation Patterns in People With SCI · not yet recruiting
NCT06923293 — Improving Walking After a Lower Limb Injury Using a Custom Motorized Orthosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02286557 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kessler Foundation
Last refreshed: 25 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02286557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing